Compare Standard Lithium Ltd (SLI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs TG Therapeutics Inc — how do they compare? Standard Lithium Ltd trades at $1.59 (market cap $398.07M), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 20.5× Standard Lithium Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and TG Therapeutics Inc for 16 Days on average.
| SLI | TGTX | |
|---|---|---|
Market Cap | $398.07M | $8.16B |
Volume | 1,564,155 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $59.06 |
52-Week Low | $1.61 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $260.98M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLI trades at $1.625, down 1.52% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has beaten EPS estimates in recent quarters. Key developments include progress toward a 2026 final investment decision for its Arkansas lithium project and new offtake agreements.
SLI presents high risk with no current revenue and negative cash flow from operations, but significant upside potential exists if its lithium projects advance. The consensus price target of $3.83 implies 136% upside, supported by 100% buy ratings from analysts. Execution risk on project timelines and funding remains the primary concern.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
